August 3, 2011
Half of the hepatitis C virus (HCV)-infected participants in a small midstage trial receiving a four-drug combination that included two Vertex Pharmaceuticals medications were able to discontinue treatment after 12 weeks, the company reported.
According to Vertex, 400 milligrams of its experimental oral drug VX-222 (a polymerase inhibitor) was administered with its recently approved Incivek (a protease inhibitor) and the standard regimen of pegylated interferon and ribavirin. The trial, known as Zenith, also revealed that 12 weeks after the combo discontinuation, 93 percent of those patients retained undetectable HCV levels.
Those patients not eligible to stop treatment at 12 weeks received another 12 weeks of standard therapy. All 13 who continued in the trial appeared cured at 24 weeks, Vertex said.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|What's Hot in HIV Cure Research?|
|Extensively Drug-Resistant HIV Yields to a New Drug: Ibalizumab|
|A Review of Long-Acting HIV Treatment and Prevention|
|Top Menu Items From the Boiling Cauldron of HIV Clinical Research|
|This Week in HIV Research: Researchers Exonerate Long-Alleged 'Patient Zero,' and Triggering bNAb Production Shows Promise|